Relative Bioavailability (rBA) of Evobrutinib Intended Commercial and Clinical Tablets, and Effect of Food on Intended Commercial Tablets
Clinical trial NCT04314024 · COMPLETED
Trial details
- NCT number
- NCT04314024
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-05-25
- Primary completion
- 2020-06-23
- Enrollment
- 18
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.